Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04762355
Other study ID # PVO-3A-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 30, 2018
Est. completion date January 3, 2019

Study information

Verified date February 2021
Source Ipsen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. The goal of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of palovarotene ophthalmic solution in healthy adult subjects.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date January 3, 2019
Est. primary completion date January 3, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Key Inclusion Criteria: - Healthy, adult, male or female, 18 to 55 years of age, inclusive, at screening. - Continuous non-smoker who had not used nicotine containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting. - Body mass index (BMI) =18.0 and =32.0 kg/m2 at screening. - Medically healthy as deemed by the Investigator or delegate and determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory results obtained within 28 days before the start of the study. - Tolerate topical administration to the eye. - Best corrected visual acuity is equal or better than 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in both eyes. Key Exclusion Criteria: - Mentally or legally incapacitated or had significant emotional problems at the time of the screening visit or expected during the conduct of the study. - History or presence of clinically significant medical (systemic or ophthalmic) or psychiatric condition or disease in the opinion of the Investigator or delegate. - History of any illness that, in the opinion of the Investigator or delegate, might have confounded the results of the study or posed an additional risk to the subject by their participation in the study. - History or presence of alcoholism or drug abuse within the past 18 months prior to the first dosing. - History or presence of hypersensitivity or idiosyncratic reaction to the study drug, systemic retinoids such as isotretinoin or related compounds (e.g., topical tretinoins, vitamin A), fluorescein, or parabens or to the inactive ingredients in the study formulation. - History of any ocular surgery or laser within the past 6 months prior to screening. - History of herpes simplex keratitis. - History or presence of: 1. Any chronic eye disease other than refractive error, incipient cataract, strabismic amblyopia, or anisometropic amblyopia. 2. Acute eye disease (such as infection, corneal abrasion, or allergy) within the past 6 months from screening. - Any currently active ocular condition that required use of topical eye drops. - Had an intraocular pressure >21 mmHg. - If ophthalmological examination at screening or Day 1 predose revealed abnormalities of the cornea, evidence of ocular infection, inflammation (dry eyes, blepharitis, allergic conjunctivitis, iritis, and uveitis), advanced or moderately injected pterygium, keratitis, narrow anterior chamber angles, clinically significant Meibomian gland dysfunction, or any finding in either the anterior segment or posterior segment of the eye, that could have compromised the study as per Investigator or delegate discretion. - Any macular integrity issues or optic nerve head (ONH) cupping/abnormality on retinal exam. - Occurrence of active seasonal allergies including ocular allergies (e.g., annual hay fever). - Needed to wear contact lenses during the study. - Positive results at screening for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus. - Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study, unless permitted by the Investigator or delegate. - Any drugs known to be significant inhibitors and inducers of CYP3A4 enzymes, including St. John's Wort, for 30 days prior to the first dosing and throughout the study. - Ocular medication of any kind (including artificial tears), antihistamines, anticholinergics, and/or oral/nasal steroids for 30 days prior to the first dosing and throughout the study. - Isotretinoin or other systemic retinoids beginning 30 days or 5 half-lives, whichever was longer

Study Design


Intervention

Drug:
Palovarotene
ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
Vehicle
Placebo-to-match palovarotene ophthalmic solution vials

Locations

Country Name City State
Canada Algorithme Pharma facility Québec

Sponsors (2)

Lead Sponsor Collaborator
Clementia Pharmaceuticals Inc. Ipsen

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and severity of treatment-emergent ocular adverse events (TEAEs) from baseline until the end of study (up to 25 days)
Primary Change in ocular safety measurements as determined by Best-Corrected Visual Acuity (BCVA) from baseline until the end of study (up to 25 days)
Primary Change in Corneal Fluorescein Staining from baseline until the end of study (up to 25 days)
Primary Change in intraocular pressure from baseline until the end of study (up to 25 days)
Secondary Plasma concentration (predose) observed at the end of a dosing interval (Ctrough) Day 5 and Day 6 (prior to the morning), Day 7 ((prior to the morning), Day 8, Day 9, Day 10
Secondary Area under the concentration-time curve during a dosing interval (AUCtau) Day 7 and Day 10
Secondary Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) Day 10
Secondary Maximum observed concentration at steady state (Cmax,ss) Day 7 and Day 10
Secondary Average concentration at steady state (Cavg) Day 7 and Day 10
Secondary Apparent total plasma clearance after topical administration (CL/F) Day 7 and Day 10
Secondary Time to reach Cmax at steady state (Tmax) Day 7 and Day 10
Secondary Apparent first-order terminal elimination half-life (t½) Day 7 and Day 10
Secondary Apparent first-order terminal elimination rate (k el) Day 7 and Day 10
Secondary Apparent volume of distribution (Vss/F) Day 7 and Day 10
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3